Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anitocabtagene autoleucel in newly diagnosed multiple myeloma
2024-517020-18-00Phase 2Authorised
- Sponsor
- PETHEMA
- Start
- Jun 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of anitocabtagene autoleucel in multiple myeloma (MM) (3 cohorts), sponsored by PETHEMA. Primary endpoints: Incidence, seriousness, and severity of all adverse events and uMRD-negative complete response rate (10^-5) at 12 months after enrollment. Planned start Jun 2025; status: authorised.
02
Drugs
anitocabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-517020-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517020-18-00.